ScanGrants is a public service listing of grants and other funding types to support health research, programs and scholarship.
11 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
Gloria Scharf Beedie Memorial Grant
The deadline for the current scholarships and grants cycle is October 15, 2014.
Sponsored by the family of Gloria Scharf Beedie
To fund the development of a new program or support an existing program that promotes patient education and / or quality of life
$1,000 and a plaque
1. Current full member of ANNA, having been a member of ANNA for a minimum of the last 2 years as of the awards/scholarship application deadline.
2. Actively involved in nephrology nursing related health care services.
3. Key participant in an education or quality of life program.
4. Program may be a new endeavor or one already established.
The application must include:
1. Letter(s) of support from the administrator, medical director, or nursing director from the institution or unit where project will be conducted.
2. Project proposal, limited to 4 double-spaced pages, to include:
a. Description of the program
b. Current clinical applicability, including relationship to the Nephrology Nursing Standards of Practice and Guidelines for Care
c. Benefit to kidney patient population
d. Demonstration of originality, creativity, and organization
e. Details of implementation
f. Itemized budget
Expectations of the Recipient
A written report of the use of the funds and the achievements as a result of the grant is to be submitted to the ANNA Board of Directors by February 1 of the following year.
Note: Blinded copies of this application and supporting documents are not necessary.
Call for Nominations: Kelly McManus Memorial Award
The deadline for the current awards cycle is October 15, 2014.
Sponsored by NxStage
To recognize a nurse who, through clinical excellence, has provided care to patients receiving frequent (daily, every other day, 5 times/week) home hemodialysis that is above and beyond the requirements of his/her position.
$2,000 and a plaque
1. Candidates for the award will be nominated.
2. Be a current full member of ANNA, having been a member for a minimum of the last 2 years as of the awards/scholarship application deadline.
3. Actively involved in nephrology nursing related health care services.
4. Active participant in ANNA at the local and/or national level.
5. Evidence of commitment and competence in the training and care of home hemodialysis patients.
6. Evidence of contributing toward improved patient care through utilization of relevant evidence-based nephrology nursing practice.
7. Committed to personal and professional growth through continuing education.
8. Involved in the continuous improvement of patient care through activities such as the following:
a. Patient recruitment and selection.
b. Demonstrating initiative to assist in the start and growth of a home hemodialysis program.
c. Patient education.
d. Other patient-centered activities.
American Society of Hematology Scholar Awards
The ASH Scholar Awards are designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator.
Awards are limited to a maximum of $100,000 for fellow scholars and $150,000 for junior faculty scholars over a two- to three-year period, with an annual maximum of $50,000 for fellows and $75,000 for junior faculty. Up to 15 percent of the award can be (but is not required to be) used for benefits, including medical and dental insurance, life insurance, and retirement benefits.
All awards are activated on July 1 of the following year. The applicant has the option of concluding the award on June 30, two or three years after activation. All award payments are made on a quarterly basis - the amount depends on whether the award is being spread over two or three years. Payments are made to the appropriate financial officer of the institution as indicated on the proposed budget within the full application.
ASH considers basic research to include a broad spectrum of studies on genes, proteins, lipids, carbohydrates, biochemical and signaling pathways, receptors, cells and animals, as well as samples obtained from humans, all of which are designed to further our understanding of the blood, bone marrow, and related organs or the pathogenesis of blood disorders. The emphasis for grants in this category should be on the discovery of new knowledge in a traditional laboratory setting.
ASH defines translational research as using knowledge of human biology to develop and test the feasibility of relevant interventions in humans and/or determine the biological basis for observations made in individuals with hematologic conditions or in populations at risk. Translational research should be founded on and directly connected to some aspect of human biology and may encompass any form of structural, biochemical, genetic, or other appropriate experimental approaches using human materials. The proposal should address clinical applications - not just test development - although the development of novel instrumentation of value to hematology is clearly within the scope of the application. Clinical trial projects with laboratory correlatives are considered clinical.
Clinical Research: ASH considers clinical/translational research to include patient-oriented research and outcomes-based research. ASH emphasizes that clinical research must involve substantial interaction with patients.
For the purposes of the ASH Scholar Awards program, patient-oriented research is defined as research conducted with human subjects and involves an investigator directly interacting with human subjects. Categories of patient-oriented research include: 1) mechanisms of human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new technologies.
ASH strongly encourages applications in outcomes-based research. Options for outcomes-based research include: 1) a decision-analysis or cost-effectiveness analysis of a relevant topic within hematology, 2) survey-based research investigating practice patterns, access to care, quality of care, clinical outcomes, or quality of life among patients with hematologic conditions, 3) retrospective analyses of large administrative databases (e.g., CMS, a large insurer, SEER) that may enlighten health care policy decisions related to hematologic disease, and 4) large scale epidemiologic or genetic epidemiologic studies that define the incidence, prevalence, prognosis, and natural history or the effects of therapy of blood disorders.
Applications that fall within any of the categories discussed above are encouraged.
Letter of Intent Due: Wednesday, May 7, 2014
Application Made Available for Those Who Successfully Submit a LOI by the Deadline: Thursday, June 5, 2014
Application Deadline Friday, August 1, 2014
Award Winners Notified: Mid-November, 2014
Activation of Award: Wednesday, July 1, 2015
These eligibility requirements are evaluated as of the date of the LOI submission.
Eligible applicants must be a citizen of the United States or Canada or hold a visa in the United States or Canada.
Eligible applicants must conduct research within the US or Canada
Scholar Award applicants are required to be members of ASH in good standing at the time of the Letter of Intent submission, and for the duration of the Scholar Award Program. If your membership application is pending at the time of the Scholar Award application deadline, you will still be considered for a Scholar Award.
To verify your membership status, please log on to the membership section of the ASH website. If you need assistance with your username and password, please contact an ASH Customer Relations Representative at email@example.com.
Fellow Scholar Awards
PhD or MD/PhD applicants must have fewer than 5 years of research experience after completion of their PhD (including research performed during fellowship, but excluding clinical fellowship time)
MD applicants should have more than 3 but fewer than 5 years of research experience (including research performed during fellowship, but excluding clinical fellowship time)
MD applicants with fewer than 3 years research experience (inclusive of fellowship research time) should consider applying for the Senior RTAF award
Applicants with the title of Assistant Professor or equivalent *must* apply for the Junior Faculty Award, regardless of research experience
Junior Faculty Scholar Awards
MD, PhD or MD/PhD applicants must have more than 5 but fewer than 10 years of research experience after completion of their PhD (including research performed during fellowship, but excluding clinical fellowship time)
Applicants with the title of Assistant Professor or equivalent *must* apply for the Junior Faculty Award, regardless of research experience.
American Society of Hematology Bridge Grant Program
All applicants must submit proposals to conduct research in hematology.
ASH considers basic research to include a broad spectrum of studies on genes, proteins, lipids, carbohydrates, biochemical and signaling pathways, receptors, hematopoietic cells, and samples obtained from human patients or from vertebrate animal models. For the purpose of this grant, hematology-related basic research is designed to further our understanding of the blood, bone marrow, and related organs and/or the pathogenesis of blood disorders. The emphasis for grants in this category should be on the discovery of new knowledge in a traditional laboratory setting.
ASH defines translational research as using knowledge of human biology to develop and test the feasibility of relevant interventions in humans and/or determine the biological basis for observations made in individuals with hematologic conditions or in populations at risk. Translational research should be founded on and directly connected to some aspect of human biology and may encompass any form of structural, biochemical, genetic, or other appropriate experimental approaches using human materials.
Patient-Oriented Clinical Research
Patient-oriented research is defined as research conducted with human subjects and involves an investigator directly interacting with human subjects. Categories of patient-oriented research include: 1) mechanisms of human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new technologies.
Options for outcomes-based research include: 1) a decision-analysis or cost-effectiveness analysis of a relevant topic within hematology, 2) survey-based research investigating practice patterns, access to care, quality of care, clinical outcomes, or quality of life among patients with hematologic conditions, 3) retrospective analyses of large administrative databases (e.g., CMS, a large insurer, SEER) that may enlighten health-care policy decisions related to hematologic disease, and 4) large scale epidemiologic or genetic epidemiologic studies that define the incidence, prevalence, prognosis, and natural history or the effects of therapy of blood disorders.
Application deadline: June 1, 2014
Application notification of acceptance: Mid-Late July, 2014
To be eligible for the ASH Bridge Grant Award all applicants must:
Have submitted a hematology-related R01 or equivalent application to NIH in the past 18 months that was scored but not funded.
ASH uses the NIH definition of R01 equivalence: “R01-equivalent awards include R01, R23, R29, and R37 activity codes and, beginning in fiscal year 2008, DP2 awards to first-time NIH investigators. Not all of these activities are in use by NIH every year.”
The 18 month timeline is linked specifically to the date your R01 was reviewed by the NIH study section.
Be an ASH member or have a pending application for membership at the time of application.
If you have a pending application and are awarded a Bridge Grant Award, your award will be conditional based upon membership approval
Hold a faculty position in an academic institution or the equivalent position in a non-profit research organization. Employees of independent research institutions are eligible to apply if they have a faculty type appointment and the institution is allowed to independently apply for and receive NIH funding.
At the time of award activation, the amount of other research funding available to the principal investigator may not exceed $250,000 annually. This amount does not include the applicant’s salary/fringe and funding from within the institution.
Hematologists eligible to apply for the ASH Scholar Award are not eligible to apply for this award.
Individuals cannot hold an ASH Scholar Award and ASH Bridge Grant concurrently. ASH Scholars can apply if their award terminates before the commencement of the bridge grant.
Applicants can apply a maximum of three times over the three-year award program.
Previous Bridge Grant award recipients cannot apply for a second award.
Call for Applications: American Society of Transplantation Transplant Nursing Grant
Applications for the AST nursing grant must be submitted by Monday, September 15, 2014. The funding for this grant has been provided by the Wood-MacMillan Foundation.
2015 Transplant Nursing Research Priorities
The AST has identified the following research prioritiy for 2015, and encourages nurses working within this area to apply for funding by the AST:
Preventing late graft failure – cellular and humoral chronic rejection, recurrent and de novo GN
This is a two-year grant ($5,000/year) awarded for studies that focus on topics related to transplant candidate and recipient outcomes and well-being, quality of life, compliance, and aspects of transplant-related drugs that affect patient care (including dosing, side effects, pharmacokinetics, and pharmacogenetics). Studies should be designed to answer specific question(s). Preference will be given to prospective studies.
The AST supports a wide range of basic, clinical, and translational research topics. Research topics that involve under-represented areas including minorities, women, and pediatrics are strongly encouraged. The AST also encourages applications from women and minority researchers. Under-represented minority investigators are defined as individuals belonging to a particular ethnic or racial group as determined by the NIH. Established AST members are encouraged to bring this funding opportunity to the attention of a new faculty members performing transplantation research at their institutions and to support their applications.
Please pay particular attention to the eligbility requirements, as requirements vary for different AST grants.
Appointment and Institutional Resources: At the time of the application, the applicant must have a staff position at an accredited medical center or institution of higher learning and be an established member of the transplant team. The applicant’s Administrative Supervisor (or Chief of Transplantation) must write a letter stipulating that the applicant has the institutional resources for conducting independent research (office space, computer, statistical back-up; access to medical records) and the applicant’s Administrative Supervisor must specifically stipulate the amount of protected research time should this grant be awarded.
Membership: The applicant must be an active member of the AST or have submitted a completed membership application by September 15, 2014 (with expectation that membership will be active before the grant review occurs). The applicant's membership dues must be paid by November 1, 2014; otherwise the application will not be considered for funding.The proposed work is to be performed in a North American Medical Center.
Education: The applicant must hold a degree and have completed any advanced training commensurate with their position at the time of the application. Nurses must have sufficient advanced training and experience to perform the proposed work. Applicants can include: staff nurses (RN), nurse practitioners (RN, NP, CRNP, FNP, ACNP), and clinical nurse specialists (CNS).
Citizenship: The applicant must be either: a) US, Canadian, or Mexican citizen; b) a lawfully admitted permanent resident foreign national of the US, Canada, or Mexico with a valid visa during the award period, or c) a foreign national admitted lawfully for residence in the US, Canada, or Mexico during the awarded period. Funding will not be released until visa status is confirmed.
Previous/Additional Funding: An individual cannot apply for the AST nursing grant if he/she has been awarded an AST faculty grant in the past or if the applicant serves as the PI on a previous or current R01, project on a P01 grant, VA Merit award or comparable non-mentored award.
Call for Applications: Cutaneous Lymphoma Foundation 2014 CLARIONS Award Program
Research Funding Priorities
The CLF’s RAP seeks to fund innovative research in all areas of cutaneous lymphomas with particular interest
• Etiology and risk factors of cutaneous lymphomas.
• Measures of disease impact on individuals and populations affected by cutaneous lymphomas.
• Translating discoveries into diagnostic and therapeutic advances in cutaneous lymphomas.
• Optimizing therapies for cutaneous lymphomas.
• Improving quality of life for individuals with cutaneous lymphomas
Eligibility and Requirements
Investigators at all levels, from clinical and post‐doctoral fellows to established investigators, are eligible to receive awards. Medical students and graduate students are not eligible. Non‐U.S. investigators are eligible and the research funded by the RAP can be conducted at non‐U.S. institutions. Investigators must be members of an established and recognized academic institution. All research projects involving human subjects must receive IRB approval.
Each year the CLF will provide two $25,000 awards, renewable for 1 year contingent upon approval by the CLF Board of Directors based upon the CLF Scientific Review Board’s review and recommendation. A small indirect cost amount between $1,000‐$2,000 is allowable.
2014 Calendar of Events for CLARIONS Research Grant Award:
July 31 - Application deadline
August - October - Scientific Review Board review
November 1 - Recipients notified of award
December - Grant awards announced at ASH meeting
January, 2015 - Disbursement of Award and beginning of new award cycle
Questions about the application process should be submitted to Holly Priebe at firstname.lastname@example.org or by calling 248‐644‐9014, extension 6.
Call for Applications: PhRMA Foundation Assessing the Benefits of Treating Cancer Research Starter Grant
Opening Date: March 2014
Closing Date: May 16, 2014
Anticipated Award Date: July 2014
Researchers and clinicians have made remarkable progress in the fight against cancer, and death rates are falling. However, the disease still causes enormous suffering and represents a substantial economic burden in the United States. While cancer medicines have extended millions of lives and offer trillions in societal benefits, this value often is not well understood or fully characterized. Social and economic benefits accrue across a range of direct and indirect effects (e.g., overall survival, quality of life, and productivity) and evolve over time as the body of evidence and standards of practice change. As our understanding of the basic science of cancer grows, and this understanding is translated into novel diagnostics and treatments, patients and society benefit from continual innovation in cancer care. The purpose of this RFP is to encourage research aimed at quantifying the benefits to society that have accrued from innovations in cancer treatment.
The grant will be awarded to candidates who establish a sound and innovative research project focused on developing a novel way of quantifying or describing the social, patient-centered, and economic benefits of innovation in cancer treatment. Relevant research goals may include developing new methods to define and measure the societal benefits from cancer care innovation (for example, contributing to an understanding of value across a wider range of outputs that can be more difficult to assess, capturing heterogeneity in patient values (such as quality of life, productivity, etc.) within and among populations, and accounting for variability in value over time and its relationship to long-term aggregate clinical gains against cancer). Examples of the types of research questions of interest include:
-- Developing a novel way of describing the benefits of treatments that accrue over time as clinicians develop a better understanding of the disease process and treatment protocols. Oftentimes, patients who are enrolled in clinical trials are in later stages of the disease; however, once a drug is approved, it may be used at an earlier stage. Thus, the benefits of treatment may not be fully realized for several years after approval.
-- Describing improvements in quality of life, productivity, or other patient-centered measures that can result from cancer treatment. Patients may value certain outcomes and benefits differently than other stakeholders; describing the heterogeneity of value across the range of stakeholders (including patients, caregivers, providers, etc) is an important step to developing a fuller picture of treatment gains beyond the traditionally reported 5- and 10-year survival rates.
-- Building a more complete picture of innovation in cancer research and treatment over time. Most scientific progress builds on earlier research and development. Scientific understanding of cancer has grown from viewing the condition as a single monolithic disease to a constellation of hundreds of different molecular pathways. As scientists elucidate these pathways, there are spillover benefits as this increased understanding of the molecular basis of disease can result in advances in other areas.
This award is not intended for clinical or bench research, and is focused on supporting research in the health economics and social science fields. Additionally, research results should be generalizable to the U.S. context. Proposals focused on methods are eligible; however, researchers must clearly indicate how these new methods will be used to capture patient, population, or societal outcomes and benefits.
Individuals holding a rank of instructor, assistant professor, or investigator at the doctoral level are eligible to apply for a research starter grant. The program is not intended for individuals in post-doctoral training programs.
Applicants must be sponsored by the department within which the proposed research is to be undertaken. Applicants must be based in an academic, healthcare, or other research institution (e.g., schools of medicine, public health, pharmacy, nursing, etc) and should have the skills and experience required to carry out the proposed work. Applications are to be submitted to email@example.com and received by May 16, 2014.
The award consists of $100,000 support for one year and is made to the university or institution on behalf of the recipient, with the understanding that the university or institution will administer the funds. The “starter” aspect of the program strives to assist individuals who are establishing careers as independent investigators with an interest in describing the benefits of cancer treatment, innovation, and progress. The funds are to be used to conduct the proposed research and provide the grantee financial support to promote future research efforts in this field. Applicants are highly encourage to seek other funds to continue research following termination of the starter grant.
Recommended guidelines for using the starter grant funds are listed below. The submitted line item budget must reflect how the funds will be used based on the guidelines:
1. The purchase data or equipment that will support the proposed research efforts.
2. The support technical assistance (e.g., technician/research assistant; not including fringe benefits).
3. No more than $1,000 may be used per year for travel to professional meetings by the grantee.
4. A percentage of the funds may be used for salary (not to exceed 25%), if the review panel determines this level of support is justified given the applicant’s current position, current funding level, and proposed research plan.
5. The program provides no other subsidies (tuition, fringe benefits, indirect institutional costs, etc).
The applicant should also identify other intramural support presently available for the proposed project and other research efforts by budget categories and amounts. If the institution makes available the services of a technician or assistant to the candidate, please note this support. Other principals involved in the project as collaborators and the amount of time developed to the project by the applicant and other principals should also be identified. Please also list by titles the funded research project of each principal, the percentage of time committed, and the amount and source of funds for these projects. Additional investigators are welcome to as collaborators in a multidisciplinary research team. The amount of time to be devoted to the project by the applicant and other co-investigators or co-applicants should be clearly described in the research proposal.
A progress report (approximately 2 pages) will be required at midterm, and a final report (approximately 10 pages) will be required upon completion of the work. The PhRMA Foundation project officer should be made aware of manuscripts to be published as a result of the proposed research. The funds are non-transferrable.
The application package must be submitted in the order listed below as a single PDF. The applicant’s name, institution, and project title should be provided as a header on the top right corner of each page. Any questions about the application or eligibility criteria should be directed to Clara Soh at firstname.lastname@example.org.
List of Application Components:
1. Introduction page, including applicant name, mentor name, institution, project title, and research abstract (300 word limit)
2. Applicant CV or biosketch
3. 1-page applicant cover letter describing why he/she is qualified to conduct the proposed research and how the fellowship award will provide training and education to help further his/her career. The letter should also state whether the applicant has any conflicts of interest.
4. Research plan (10 page limit, 12 point font; single spaced, with 1” margins, bibliography excluded from page limit restriction) that includes a brief abstract and comprehensive description of the research plan. Applicants are requested to include a description of the study objective(s), conceptual framework, rationale, key measures, methodology, known limitations, expected findings, and significance/potential impact of the findings. Preliminary results, if any, should also be included. The proposal should state plans for dissemination of research findings (i.e., expected peer-reviewed publications, poster, or paper presentation at research meetings).
5. Budget, with breakdown of how funds will be used and any other anticipated sources of funding
6. Reprints of relevant articles published or co-authored by applicant
7. Contact information and CV/biosketch of applicant’s mentor/dissertation chair
8. Letter of recommendation from mentor/dissertation chair (1 page limit). The proposed research should be directed under the guidance of a mentor. The mentor must provide a letter of recommendation that certifies that formal mentorship will be available to ensure adequate training of the applicant and encourage progression of the study. The letter should also describe why the applicant’s potential and experience qualifies them to conduct the proposed research. The research record of the mentor and a description of how the mentored experience will enhance the applicant’s research objective(s) should also be included. The letter should describe how often and in what setting the mentor will engage with applicant (e.g., weekly meetings). The letter should also state whether the mentor has any conflicts of interest related to the proposed research. No more than one letter of recommendation is required or permitted.
Review Process and Criteria
Applications will be judged on the scientific worthiness of the proposed research and will be evaluated by a panel of qualified reviewers selected by the PhRMA Foundation. Reviewers may offer written critiques or suggestions of the proposal; award recipients are expected to incorporate reviewer feedback into their research. The review criteria will include the following (weight included in parenthesis):
-- Potential impact of research findings (20%)
-- Study approach and methodology (20%)
-- Innovativeness (20%)
-- Potential to stimulate further downstream research (15%)
-- Research environment/mentorship (10%)
-- Generalizability (10%)
-- Feasibility (5%)
Call for Applications: Livestrong Foundation Big C Competition
We're looking for big thinkers to create tangible innovations and solutions improving the daily lives of people facing cancer.
The Big C competition is an opportunity to change the way the world fights cancer.
How it Work
May 15 deadline for submitting your product, service or innovation.
150 semi-finalists have access to mentoring, crowdfunding and media exposure.
Five teams pitch in Austin for a chance to win $25,000!
(60 teams win a total of $140,000)
Solutions We Seek
The Big C competition invites you to submit projects addressing the following needs.
Rebuild Financial Health
Regain Emotional Wellbeing
Care for Caregivers
Improve Access to Quality Care
Fill the Knowledge Gap
Help Anyone Facing Cancer Now
Call for Applications: Sigma Theta Tau International/Hill-Rom Environment of Elder Care Nursing Research Grant
The Environment of Elder Care Nursing Research Grant co-sponsored by Hill-Rom will advance the science of nursing through research focused on critical aspects of elder care including clear lungs, no falls, safe skin, patient comfort and ease-of-use. Applications from novice researchers who have received no other national research funds are encouraged. Preference will be given to Sigma Theta Tau International members, other qualifications being equal.
Funds for this grant are provided by Hill-Rom. Allocation of funds is based on the quality of the proposed research, the future promise of the applicant and the applicant's research budget.
Funds for this grant do not cover expenses incurred prior to the funding date.
Registered nurse with a current license.
Hold at minimum a master's degree or its equivalent, and/or be enrolled in a doctoral program.
Submission of completed research application packet and a signed research agreement via our online submission system.
Ready to implement research project when funding is received.
Submit to STTI a final report; submit completed abstract to STTI's Virginia Henderson Global Nursing e-Repository.
Submit an abstract for publication to Hill-Rom regarding the research done as a product of the grant, and credit research grant partners in all publications and presentations of the research.
Grants available: 1 per year
Funding: up to US $9,000
Deadline: 1 July 2014
Funding date: 1 November 2014
Sigma Theta Tau International
Phone: 888.634.7575 (US/Canada) or +1.317.634.8171(International)
How to apply: All applications must be submitted via the online submission system.
Scleroderma Foundation Research Grant Funding Program
The grant application deadline is 5 p.m. Eastern Sept. 15 each year. (Note: If the grant deadline falls on a weekend, the following Monday will be the deadline.)
Appropriate Areas of Research and Criteria
Appropriate research areas may include but are not limited to the following as they relate to scleroderma:
Studies of animal models.
Mechanisms of end organ damage.
Endothelial cell biology.
Models and markers of gender and genetic factors.
Stem cell biology.
Health services research (e.g. quality of life, health care delivery.)
Study of clinical manifestation.